dorsaVi Ltd. announced the appointment of Dr. Michael Winlo to its Board of Directors as Non-Executive Director effective 25 October 2023. Dr. Winlo is a distinguished medical professional and entrepreneur with proven leadership experience across the biotechnology, pharmaceutical and technology sectors. He is currently Chief Executive Officer and Managing Director of Emyria Limited, as well as a Non-Executive Director of Nanoveu Limited.

Dr. Winlo also serves as a Director and former CEO of Linear Clinical Research, a world-class provider of early and late-stage pharmaceutical trial facilities and management services. Prior to his role at Linear, Dr. Winlo was based in Silicon Valley for five years as the Health Lead at Palantir Technologies. dorsaVi looks forward to leveraging Dr. Winlo's extensive managerial experience combined with his deep knowledge of the global healthcare landscape to propel dorsaVi's growth strategy.

Dr. Winlo holds a Bachelor of Medicine, Bachelor of Surgery (MBBS) from the University of Western Australia and a Master of Business Administration (MBA) from Stanford University.